Results 61 to 70 of about 2,435 (141)

ID-44 Perfil de Distribuição da Terapia Tripla para Tratamento da Fibrose Cística no 2º Semestre de 2024

Jornal de Assistência Farmacêutica e Farmacoeconomia
Objetivo: Analisar o perfil de distribuição do medicamento que representa uma tripla terapia para fibrose cística, consistindo na associação elexacaftor, tezacaftor e  ivacaftor, possuindo duas apresentações: elexacaftor 50 mg + tezacaftor 25 mg ...
Flavia Kimura Okamoto, Marcelo Azevedo Coutinho   +1 more
doaj   +1 more source

Rethinking hyperbilirubinemia: Gilbert syndrome in children with cystic fibrosis, a case report

Respiratory Medicine Case Reports
Cystic Fibrosis leads to liver complications, including cystic fibrosis liver disease but hyperbilirubinemia in CF patients on CFTR modulators is less understood.
Yara Salameh, John Lyles, Shatha Yousef
doaj   +1 more source

The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study

BMC Pulmonary Medicine
Background Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients.
Nela Stastna, Lenka Hrabovska, Pavel Homolka, Lukas Homola, Michal Svoboda, Kristian Brat, Libor Fila   +6 more
doaj   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis: A Meta-Analysis of Randomized Control Trials

International Journal of Medical Students
Background: The Cystic Fibrosis (CF) modulator medication Elexacaftor-Tezacaftor-Ivacaftor (ETI) demonstrated remarkable efficacy for persons with at least one F508del allele, a condition that affects at least 85% of CF patients.
Deekshitha Alla, Ananya Mehta, Sri Anjali Gorle, Dhruv Shah, Sai Santhosha Mrudula Alla, Gayatri Ghadvaje, Naga Laxmi Poojita Avula, Aradhya Singh, Sai Lokesh Moraboina, Abhik Halder, Vamsi Krishna Kondepati   +10 more
doaj  

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators

Frontiers in Pharmacology
IntroductionCystic Fibrosis (CF) is a genetic disease due to loss-of-function mutations of the CFTR channel. F508del is the most frequent mutation (70% of alleles in Italy), while other mutations have much lower frequency.
Valeria Tomati, Valeria Capurro, Emanuela Pesce, Cristina Pastorino, Elvira Sondo, Mariateresa Lena, Mariateresa Lena, Anna Borrelli, Federico Cresta, Stefano Pantano, Francesca Collini, Pietro Ripani, Vito Terlizzi, Cristina Fevola, Stefano Costa, Maria Cristina Lucanto, Federico Zara, Federico Zara, Tiziano Bandiera, Renata Bocciardi, Renata Bocciardi, Carlo Castellani, Luis J. V. Galietta, Nicoletta Pedemonte   +23 more
doaj   +1 more source

The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes

Journal of Clinical & Translational Endocrinology
Objective: Patients with Cystic Fibrosis related diabetes [CFRD] are treated with insulin and high calorie diets to maintain body mass. The combined CFTR modulator elexacaftor/tezacaftor/ivacaftor [ETI] decreases pulmonary exacerbations and improves ...
Mehdia Amini, Kevin Yu, Jessica Liebich, Vaishaliben Ahir, Emily Wood, Stewart Albert, Sandeep Dhindsa   +6 more
doaj   +1 more source

Adult Diagnosis of Cystic Fibrosis: A Cause of Recurrent Pneumonia

Annals of Internal Medicine: Clinical Cases
We describe a patient presenting for evaluation of nearly annual pneumonias since the age of 9 years, eventually requiring multiple hospitalizations. Genetic testing revealed compound heterozygous mutations for 2184insA and L206W, indicative of cystic ...
Amira Elsabagh, Ashley Dean, Anthony Loschner   +2 more
doaj   +1 more source

Drug Responsiveness in Patient-Derived Rectal Organoids Correlates with Clinical Response in CF Subjects: A Real-Life Analysis

Scientia Pharmaceutica
Pharmacological modulators of CFTR have significantly changed the cystic fibrosis (CF) phenotype of subjects affected by this multi-organ disease.
Karina Kleinfelder, Paola Lecca, Roberta Valeria Latorre, Chiara Mortali, Sara Casati, Sofia Vanerio, Claudio Sorio, Paola Melotti   +7 more
doaj   +1 more source

Personalised CFTR Modulator Treatment Initiation and Monitoring in CF‐Related Liver Disease: When Less Is More

Respirology Case Reports
Hepatotoxicity due to Elexacaftor/Tezacaftor/Ivacaftor (ETI) use has been well documented. There are no dose adjustments or increased‐frequency monitoring algorithms recommended for people who experience elevated transaminases without cirrhosis, only ...
Sona Vekaria, Grace Kavanagh, Siobhain Mulrennan   +2 more
doaj   +1 more source

Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. [PDF]

Eur Respir J
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS, CHEC-SC investigators.   +10 more
europepmc   +1 more source